We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves AstraZeneca Antibody for Lupus After Previous Rejection
FDA Approves AstraZeneca Antibody for Lupus After Previous Rejection
Three years after it missed a key endpoint in its first phase 3 trial, AstraZeneca’s monoclonal antibody Saphnelo (anifrolumab-fnia) turned things around and has now garnered FDA approval for the treatment of adult patients with moderate-to-severe systemic lupus erythematosus (SLE), the most common form of lupus.